Bluejay Diagnostics, Inc. - Common Stock (BJDX)

Completes SYMON-II clinical study enrollment and advances clinical validation activities.Achieves critical manufacturing milestone ahead of contractual deadline, strengthening supply chain and commercialization readiness.Targets FDA 510(k) submission in the first half of 2027.

ACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes through its Symphony™ near-patient diagnostic platform, today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the "Reverse Stock Split"). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on November 3, 2026, and the Company's common stock will open for trading on The Nasdaq Capital Market on a post-split basis on November 3, 2026 under the Company's existing trading symbol, "BJDX." At such time, the Company's common stock will also commence trading with a new CUSIP number, 095633707.

Company Achieves Toray Contractual Milestone with Establishment of Manufacturing Site

SYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission

Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by

August 31, 2026 - Investors searching for emerging-growth opportunities near the $0.50 level are watching a group of NASDAQ-listed companies with catalysts spanning AI data centers, high-performance computing, military drones, Edge AI, cybersecurity, battery materials and medical diagnostics . FingerMotion, Inc. (NASDAQ: FNGR), E-Power Inc. (NASDAQ: EPOW), Peraso Inc. (NASDAQ: PRSO), Cyabra, Inc. (NASDAQ: CYAB), Bluejay Diagnostics, Inc. (NASDAQ: BJDX) and Fangdd Network Group Ltd. (NASDAQ: DUO) each have developments that could keep them in focus among microcap and small-cap investors.

Aug. 5, 2026 – Investors continue scanning the sub-$1 market for companies generating significant news flow, strategic developments, and potential turnaround opportunities. Among the names attracting attention are Reitar Logtech Ltd. (NASDAQ: RITR), IGC Pharma, Inc. (NYSE American: IGC), Bluejay Diagnostics, Inc. (NASDAQ: BJDX), and C3is Inc. (NASDAQ: CISS), while several OTC companies are also drawing increased interest.

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) stock increased by 107.0% to $2.65 during Wednesday's regular session. The company's market cap stands at $60.6 million. Bluejay Diagnostics (NASDAQ:BJDX) shares

Gainers Bluejay Diagnostics (NASDAQ:BJDX) shares moved upwards by 43.0% to $1.43 during Wednesday's pre-market session. The company's market cap stands at $1.0 million. Estrella Immunopharma (NASDAQ:ESLA)

Gainers Bluejay Diagnostics (NASDAQ:BJDX) stock moved upwards by 42.0% to $1.42 during Tuesday's after-market session. American Well (NYSE:AMWL) stock rose 12.76% to $11.75. The market value of their outstanding